Monte Rosa Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Monte Rosa Therapeutics sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Monte Rosa Therapeutics: 3 sponsored US clinical trials, 1 recruiting.
Monte Rosa Therapeutics sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is NSCLC With High or Low L-MYC or N-MYC Expression, with 1 trials.
Upper-quartile sponsor footprint
Monte Rosa Therapeutics sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
NCT07119125
Study of Oral MRT-2359 in Selected Cancer Patients
NCT05546268
First-in-human Study of MRT-6160 in Healthy Subjects
NCT06597799
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
What is open in the Monte Rosa Therapeutics pipeline
1 recruiting of 3 indexed (33% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: NSCLC With High or Low L-MYC or N-MYC Expression (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Monte Rosa Therapeutics: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Monte Rosa Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Monte Rosa Therapeutics page
3 registered trials is a research-attention snapshot, not an endorsement of Monte Rosa Therapeutics or any single study.
- 1 of Monte Rosa Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- NSCLC With High or Low L-MYC or N-MYC Expression is the condition Monte Rosa Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See NSCLC With High or Low L-MYC or N-MYC Expression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Monte Rosa Therapeutics pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.